Material transfer agreements: what Indian faculty should check before sending or receiving research samples
Material transfer agreement (MTA) guide for Indian faculty: key clauses, who signs, NBA and HMSC rules for sending samples abroad, and the mistakes to avoid.
A material transfer agreement (MTA) is a contract that sets the terms when research material such as cell lines, plasmids, strains, compounds or samples moves between institutions. Before you sign or send, check what counts as the material and its derivatives, whether use is limited to research, who owns inventions you make with it, whether publication can be delayed, and who signs. In India, sharing biological resources or results with foreign parties can also need National Biodiversity Authority approval, and sending human samples abroad in a collaboration needs Health Ministry's Screening Committee clearance.
A collaborator in another university asks for your cell line. A company offers to send you a proprietary compound to test. A lab abroad wants a set of your clinical samples. In each case, before anything leaves or enters your lab, there should be a material transfer agreement. Many faculty sign these as a formality, or skip them entirely when the request comes from a friend. That is where problems start: lost patent rights, delayed papers, and sometimes a regulatory breach.
This guide explains what an MTA is, the clauses that matter, the Indian approvals that apply to biological material, and what to check before you send or receive anything.
The short answer
An MTA is a contract that governs how tangible research material moves from a provider to a recipient, and what the recipient may do with it. Before you sign, check five things: what the material includes, what use is allowed, who owns what you invent, how publication is handled, and who signs for your institution. For biological material crossing borders, also check National Biodiversity Authority (NBA) rules and, for human samples, Health Ministry's Screening Committee (HMSC) clearance.
What an MTA covers
WIPO describes MTAs as agreements that govern the transfer of physical assets and tangible research materials from a provider to a recipient, for the recipient's own research. They set each party's rights and obligations, including rights in derivative materials, results and related IP.
Typical materials include cell lines, plasmids, antibodies, microbial strains, animal models, chemical compounds, tissue or blood samples and prototype devices. The MTA does not usually cover know-how or data on their own. Those go under a confidentiality agreement or a data sharing agreement.
The clauses that matter
The Uniform Biological Material Transfer Agreement (UBMTA), published by the US National Institutes of Health in 1995 with input from universities and industry, is a useful reference because many MTAs borrow its structure.
1. Definition of the material. Under the UBMTA, "Material" means the original material, its progeny (unmodified descendants, such as cells from a cell line) and unmodified derivatives (such as subclones or a monoclonal antibody from a hybridoma). Modifications are new substances the recipient makes that contain or incorporate the material. This distinction decides ownership later, so read it carefully.
2. Permitted use. Usually teaching and academic research only. Use in humans, clinical trials or diagnostics typically needs the provider's written consent. The material often must stay in the named scientist's lab.
3. No onward transfer. You cannot pass the material to anyone else. Requests from others go back to the provider.
4. Commercial use. Selling, licensing or transferring the material to a company, or using it in contract research, is usually excluded. The UBMTA does not treat industry-sponsored academic research as automatically commercial, but some MTAs do, so check if your project has an industry sponsor.
5. Ownership of inventions. Under the UBMTA model, the provider keeps the original material, and the recipient owns its modifications, excluding the provider's material. The recipient may file patents but must tell the provider about claims on modifications or on methods of making or using the material. Commercial use needs a separate licence.
6. Publication. The UBMTA does not stop or delay publication, and asks you to acknowledge the source. Company MTAs often ask for a review period before you publish.
7. Warranty and liability. Material comes "as is", with no warranty. The recipient is responsible for its own use, storage and disposal.
8. Return or destruction. At the end, you return or destroy the material as the provider directs.
Two kinds of MTA you will meet
Read ownership and publication clauses most carefully in company MTAs.
The red flags in a company MTA
Industry MTAs are often fair, but some clauses deserve a second look before you sign:
- Reach-through rights. A clause giving the provider ownership of, or a free licence to, any invention you make using the material, even where their material is a small input. The NIH's 1999 research tools principles called reach-through royalty terms inconsistent with good practice for research tools.
- Publication approval. The NIH principles treat a 30 to 60 day review for patent filing or confidentiality as reasonable, but editorial control or approval of your paper as unacceptable.
- Conflict with other sponsors. If your project is funded by another company or a government scheme, an MTA giving rights to the provider can conflict with that agreement.
- Unlimited confidentiality. Results you cannot publish or use in a thesis are a problem for your students.
If a clause worries you, your TTO or IPR cell can negotiate it. Providers expect this.
Indian approvals for biological material
When the material is biological and crosses a border, contract terms are not the only issue.
Biological resources and the NBA. Under the Biological Diversity Act 2002, as amended in 2023, sharing the results of research on Indian biological resources or associated traditional knowledge with foreign persons or foreign-controlled entities generally needs prior approval of the National Biodiversity Authority. There are exceptions, for example for publication that follows central government guidelines and for collaborative research that meets the Act's conditions. Seeking a patent based on such research also has NBA steps. The forms and procedure were updated under the Biological Diversity Rules 2024, so check the NBA's current forms before you send material or results abroad.
Human samples and HMSC. For international collaborative research involving human biological material, ICMR's guidance requires clearance from the Health Ministry's Screening Committee. ICMR says a duly signed MTA is required (it provides a template), and that transfer of all samples to a foreign lab is not permissible. Representative samples for quality checks are allowed only from a small share of participants. You will also need ethics committee approval.
Dual-use items. Some organisms, toxins and materials fall under India's SCOMET export control list. Exporting them without authorisation draws penalties, so check the list if your material could be dual-use.
A pre-shipment checklist
Before any material leaves or enters your lab
- Tell your TTO or IPR cell first. Send the request and any draft MTA.
- Protect IP before sharing. If your material embodies an unfiled invention, sharing it can create disclosure risk. Submit an invention disclosure first. Our guide on writing an invention disclosure explains how.
- Read the key clauses. Material definition, use, ownership, publication.
- Check approvals. NBA for biological resources going abroad, HMSC for human samples in international projects, SCOMET for dual-use items.
- Get the right signature. At IIT Kanpur, for example, the Dean of R&D signs agreements and faculty cannot sign without the Director's special approval. Most institutions work similarly.
- Keep a record. File the signed MTA with your lab notebook. If an invention later arises, it shows where the material came from.
Common mistakes
- Shipping on a handshake. No MTA means no clarity on ownership if a discovery follows.
- Signing personally. You may bind yourself, not your institution, and breach your institution's policy.
- Missing the student angle. A PhD student's thesis may depend on results the MTA restricts. Our guide on who owns a PhD student's invention covers ownership questions.
- Ignoring NBA rules when sending Indian strains, plant extracts or results to a foreign collaborator.
- Sharing before filing, then finding that the disclosure counts against your own patent. See published before filing.
Getting help
MTAs are often the first agreement a faculty member handles, and the clauses can be hard to judge alone. TT Co-Pilot, Zernyx's AI assistant for technology transfer, built for TTO teams and university faculty on Zernyx's proprietary technology licensing dataset, can help you understand what each clause means before you sit down with your TTO.
FAQ
Can I sign an MTA myself? Usually not. Your institution's designated officer signs. Check your IP policy.
Does an MTA stop me from publishing? It should not. A short review of about 30 to 60 days is reasonable; approval of your paper is not.
Who owns inventions made with received material? Under the UBMTA model, you own your modifications, excluding the provider's material. Company MTAs may differ.
Do I need approval to send human samples abroad? For international collaborative projects, yes: HMSC clearance and a signed MTA, under ICMR's guidance.
Is there a standard template? The UBMTA and NIH Simple Letter Agreement internationally; in India, ICMR's HMSC template and institutional templates such as those of AIIMS and IIT Kanpur.